微卫星不稳定性判断结直肠癌预后和预测化疗疗效相关研究进展

刘锐; 寿涛; 周礼鲲; 沈丽达

doi:10.3969/j.issn.1000-8179.2013.04.015

微卫星不稳定性判断结直肠癌预后和预测化疗疗效相关研究进展

doi: 10.3969/j.issn.1000-8179.2013.04.015

刘锐^①,
寿涛^①,
周礼鲲^②,
沈丽达^③, ,

①.
云南省第一人民医院肿瘤综合治疗中心内科（昆明市061001）
②.
天津医科大学附属肿瘤医院消化肿瘤内科
③.
昆明医科大学第三附属医院肿瘤内一科

详细信息

通讯作者:
沈丽达 ShenLida2560@qq.com

计量
- 文章访问数: 25
- HTML全文浏览量: 1
- PDF下载量: 1
- 被引次数: 0
出版历程
- 收稿日期: 2012-03-17
- 修回日期: 2012-08-24

Research progress of microsatellite instability's judging prognosis and response to chemotherapy in colorectal cancer

Rui LIU^①,
Tao SHOU^①,
Likun ZHOU^②,
Lida SHEN^{③
, ,}

①.
Department of Medical Oncology, First People's Hospital of Yunnan, Kunming 650032, China
②.
Department of Digestive Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
③.
No.1 Department of Medical Oncology, The Third Hospital Affiliated to Kunming Medical University, Kunming 650118, China

More Information

Corresponding author: Lida SHEN; E-mail: ShenLida2560@qq.com

摘要

摘要: 结直肠癌是一种常见恶性肿瘤, 近年来, 微卫星不稳定性与结直肠癌的关系成为判断结直肠癌预后和预测化疗疗效方面研究的一个热点。微卫星不稳定性在判断结直肠癌的预后及指导结直肠癌的化疗方面有着重要作用。本文从微卫星不稳定性的概念, 与结直肠癌预后相关性, 与各期结直肠癌氟尿嘧啶类药物疗效间相关性等方面对微卫星不稳定性在结直肠癌中的相关进展进行综述, 旨在为临床上应用微卫星不稳定性指导结直肠癌治疗方面提供相关依据。 < /span >
- 结直肠癌 /
- 微卫星不稳定性 /
- 预后 /
- 化疗
Abstract: Colorectal cancer(CRC) is one of the most common cancers worldwide. Microsatellite instability(MSI) is an important factor of prognosis that is essential in guiding CRC chemotherapy. Remarkable progress has been achieved in the management of CRC in recent years. Prognosis is better for patients with high-MSI(MSI-H) CRCs. The relationship between MSI status and response to chemotherapy is controversial. Many studies indicate that the good prognosis of MSI-H colorectal cancer is weakened by fluorouracil.
- colorectal cancer /
- microsatellite instability /
- prognosis /
- chemotherapy

HTML全文

参考文献(29)

[1]	Goldberg RM, Meropol NJ, Tabernero J, et al. Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer [J]. Gastrointest Cancer Res, 2009, 3(Suppl 2): S23-S27. https://pubmed.ncbi.nlm.nih.gov/19352463/
[2]	张思维, 雷正龙, 李光琳, 等. 中国肿瘤登记地区2005年发病死亡资料分析[J]. 中国肿瘤, 2009, 18(12): 973-979. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU200912013.htm
[3]	Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer[J]. N Engl J Med, 2009, 361(25): 2449-2460. doi: 10.1056/NEJMra0804588
[4]	Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer[J]. Cancer Res, 1998, 58(22): 5248-5257. https://pubmed.ncbi.nlm.nih.gov/9823339/
[5]	Pino MS, Chung DC. Microsatellite instability in the management of colorectal cancer[J]. Expert Rev Gastroenterol Hepatol, 2011, 5 (3): 385-399. doi: 10.1586/egh.11.25
[6]	Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer[J]. N Engl J Med, 2000, 342(2): 69-77. doi: 10.1056/NEJM200001133420201
[7]	Benatti P, Gafà R, Barana D, et al. Microsatellite instability and colorectal cancer prognosis[J]. Clin Cancer Res, 2005, 11(23): 8332-8340. doi: 10.1158/1078-0432.CCR-05-1030
[8]	Roth AO, Tejpar S, Delorenzi M, et al. Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial [J]. J Clin Oncol, 2010, 28(3): 446-474. doi: 10.1200/jco.2009.27.15_suppl.4002
[9]	Merokl MA, Ahlquist TE, Røyrvik EC, et al. Microsatellite instability has a positive prognostic impact on stage Ⅱ colorectal cancer after complete resection: results from a large, consecutive Norwegian series[J]. Annals of Oncology, 2012, 12, [Epub ahead of print]. https://www.sciencedirect.com/science/article/pii/S0923753419372357
[10]	Koopman M, Kortman GA, Mekenkamp L, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer[J]. Br J Cancer, 2009, 100(2): 266-273. doi: 10.1038/sj.bjc.6604867
[11]	Braun MS, Richman SD, Quirke P, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial[J]. J Clin Oncol, 2008, 26(16): 2690-2698. doi: 10.1200/JCO.2007.15.5580
[12]	Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis[J]. J Clin Oncol, 2005, 23(3): 609-618. doi: 10.1200/JCO.2005.01.086
[13]	Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer[J]. N Engl J Med, 2003, 349(3): 247-257. doi: 10.1056/NEJMoa022289
[14]	Storojeva I, Boulay JL, Heinimann K, et al. Prognostic and predictive relevance of microsatellite instability in colorectal cancer[J]. Oncol Rep, 2005, 14(1): 241-249. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM15944796
[15]	Lanza G, Gafà R, Santini A, et al. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage Ⅱand Ⅲ colorectal cancer patients[J]. J Clin Oncol, 2006, 24(15): 2359-2367. doi: 10.1200/JCO.2005.03.2433
[16]	Kim GP, Colangelo LH, Wieand HS, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study[J]. J Clin Oncol, 2007, 25(7): 767-772. doi: 10.1200/JCO.2006.05.8172
[17]	Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer[J]. J Clin Oncol, 2010, 28(20): 3219-3226. doi: 10.1200/JCO.2009.27.1825
[18]	Hong SP, Min BS, Kim TI, et al. The differential impact of microsatellite instability as a marker of prognosis and tumour response between coloncancer and rectal cancer[J]. Eur J Cancer, 2012, 48(8): 1235-1243. doi: 10.1016/j.ejca.2011.10.005
[19]	Carethers JM, Chauhan DP, Fink D, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil[J]. Gastroenterology, 1999, 117(1): 123-131. doi: 10.1016/S0016-5085(99)70558-5
[20]	Des Guetz G, Schischmanoff O, Nicolas P, et al. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis[J]. Eur J Cancer, 2009, 45(10): 1890-1896. doi: 10.1016/j.ejca.2009.04.018
[21]	Des Guetz G, Uzzan B, Morere JF, et al. Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer. Cochrane Database Syst Rev[J]. 2010, 20(1): CD007046. https://pubmed.ncbi.nlm.nih.gov/20091614/
[22]	Capdevila J, Elez E, Peralta S, et al. Oxaliplatin-based chemotherapy in the management of colorectal cancer[J]. Expert Rev Anticancer Ther, 2008, 8(8): 1223-1236. doi: 10.1586/14737140.8.8.1223
[23]	Zaanan A, Cuilliere-Dartigues P, Guilloux A, et al. Impact of p53 expression and microsatellite instability on stage Ⅲ colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin[J]. Ann Oncol, 2010, 21(4): 772-780. doi: 10.1093/annonc/mdp383
[24]	Kim ST, Lee J, Park SH, et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy[J]. Cancer Chemother Pharmacol, 2010, 66(4): 659-667. doi: 10.1007/s00280-009-1206-3
[25]	Brueckl WM, Moesch C, Brabletz T, et al. Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy[J]. Anticancer Res, 2003, 23(2C): 1773-1777. http://europepmc.org/article/MED/12820457
[26]	Liang JT, Huang KC, Lai HS, et al. High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage Ⅳ sporadic colorectal cancer after palliative bowel resection. Int[J]. J Cancer, 2002, 101 (6): 519-525. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM12237891
[27]	Muller CI, Schulmann K, Reinacher-Schick A, et al. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group[J]. Int J Colorectal Dis, 2008, 23(11): 1033-1039. doi: 10.1007/s00384-008-0504-2
[28]	Koopman M, Kortman GA, Mekenkamp L, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer[J]. Br J Cancer, 2009, 100(2): 266-273. doi: 10.1038/sj.bjc.6604867
[29]	Des Guetz G, Mariani P, Cucherousseto J, et al. Microsatellite instability and sensitivity to FOLFOX treatment in metastatic colorectal cancer[J]. Anticancer Res, 2007, 27(4C): 2715-2719. https://pubmed.ncbi.nlm.nih.gov/17695437/